… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … (SAB) with leaders in inherited retinal disease and RNAtherapy. In February, ProQR announced its participation in …
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
